SECURITIES AND EXCHANGE COMMISSION FORM 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Filing Date: 2019-02-28 | Period of Report: 2019-02-28 SEC Accession No. 0001193125-19-055826 (HTML Version on secdatabase.com) FILER MorphoSys AG Mailing Address Business Address SEMMELWEISSTR. 7 SEMMELWEISSTR. 7 CIK:1340243| IRS No.: 000000000 | State of Incorp.:2M | Fiscal Year End: 1231 PLANEGG 2M 82152 PLANEGG 2M 82152 Type: 6-K | Act: 34 | File No.: 001-38455 | Film No.: 19640648 49 89 89927-0 SIC: 2834 Pharmaceutical preparations Copyright © 2019 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF A FOREIGN ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For February 28, 2019 Commission File Number 1-38455 MorphoSys AG Semmelweisstrasse 7 82152 Planegg Germany (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes ☐ No ☒ If Yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): Copyright © 2019 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Exhibits 99.1 Presentation: Company Update February 2019 Copyright © 2019 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. MORPHOSYS AG (Registrant) Date: February 28, 2019 By: /s/ Jens Holstein Name: Jens Holstein Title: CFO By: /s/ Nicola Thomas Name: Nicola Thomas Title: Specialist Corporate Communications and Investor Relations Copyright © 2019 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Engineering the Medicines of Tomorrow Company Update February 2019 Exhibit 99.1 Copyright © 2019 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Thisongoing communication clinical research contains programs certain may forward-looking not support registration statements or concerning further development the MorphoSys of its groupproduct of candidatescompanies, due including to safety its, effinancialficacy or guidance other reasons), for 2018, MorphoSys’ the commencement,s reliance ontiming collaborations and results with of clinical third parties, trials and estimating release ofthe clinical commercial data both potential in respect of its ofdevelopment its proprietary programs product and candidates other risks and indicated of product in thecandidates risk factors of its included collaborators, in MorphoSys’ the developments Registration of commercial Statement capabilities, on Form F-1 in and particular other filings with respect with the to US MOR208, Securities and and the Exchange transition Commission.of MorphoSys Given to a fully these integrated uncertainties, biopharmaceutical the reader is advised company not, tothe place expected any unduetime of reliance launch onof MOR208,such forward-looking interaction withstatements. regulators, These including forward-looking the potential statements approval speak of MorphoSys’ only as of thes current date of or publication future drug of candidates, this document. including MorphoSys discussions expressly with thedisclaims FDA regarding any obligation the potential to update approval any such to marketforward-looking MOR208, statements and expected in this royalty document and milestone to reflect payments any change in connectionin its expectations with MorphoSys’ with regards collaborations.thereto or any change The forward-looking in events, conditions statements or circumstances contained herein on which represent any thesuch judgment statement of is MorphoSys based or that as mayof the af datefect ofthe this likelihood release andthat involveactual results known will and dif unknownfer from risksthose and set uncertainties,forth in the forward-looking which might cause statements, the actual unless results, specifically financial required condition by and law liquidity or regulation., performance The compounds or achievements discussed of in MorphoSys, this slide presentation or industry areresults, investigational to be materially products different being from developed any historic by MorphoSys or future results,and its partnersfinancial and conditions are not currentlyand liquidity approved, performance by the U.S. or achievements Food and Drug expressed Administration or implied (FDA), by such European forward-looking Medicine Agencystatements. (EMA) In addition, or any other even regulatoryif MorphoSys’ authoritys results, (except performance, for guselkumab/T financialremfya®). condition Thisand liquidity presentation, and includesthe development forward-looking of the industry statements. in which © MorphoSys it operates AG,are consistent February 2019with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are that MorphoSys’s expectations regarding its 2018 results of operations may be incorrect, MorphoSys’s expectations regarding its development programs may be incorrect, the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements (including that MorphoSys may fail to obtain regulatory approval for MOR208 and that data from MorphoSys’s Copyright © 2019 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document © MorphoSys AG, February 2019 Investment Highlights Proprietary Technology Platforms Proven antibody capability Novel antibody-based and peptide formats MOR208 FDA breakthrough therapy designation for lenalidomide combination in r/r DLBCL Planned regulatory filing in 2019 MOR106, MOR202, MOR103, MOR210 Differentiated product candidates from proprietary development activities MorphoSys US Inc. Preparing for U.S. commercialization of MOR208 Broad Clinical Pipeline Proprietary and partnered clinical pipeline: 29 product candidates Tremfya® First-in-class anti-IL-23 antibody provides strongly growing royalty stream Copyright © 2019 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document * Phase 1 in healthy volunteers completed; currently in preclinical investigation 29 Product Candidates in Clinical Development, One Product Launched © MorphoSys AG, February 2019 Our Clinical Pipeline Program Partner Target Disease area Phase 1 Phase 2 Phase 3 Launched Tremfya® (guselkumab) Janssen IL-23p19 Psoriasis Gantenerumab Roche Amyloid-ß Alzheimer’s disease MOR208 - CD19 Hematological malignancies Anetumab ravtansine (BAY94-9343) Bayer Mesothelin (ADC) Solid tumors BAY1093884 Bayer TFPI Hemophilia BHQ880 Novartis DKK-1 Multiple myeloma Bimagrumab (BYM338) Novartis ActRIIB Metabolic diseases CNTO6785 Janssen - Inflammation Ianalumab (VAY736) Novartis BAFF-R Inflammation MOR103/GSK3196165 GSK GM-CSF Inflammation MOR106 Novartis/Galapagos IL-17C Inflammation MOR202 I-Mab Biopharma CD38 Multiple myeloma NOV-12 (MAA868) Novartis Factor XI Prevention of thrombosis Setrusumab (BPS804) Mereo/Novartis Sclerostin Brittle bone syndrome Tesidolumab (LFG316) Novartis C5 Eye diseases Utomilumab (PF-05082566) Pfizer 4-1BB Cancer Xentuzumab (BI-836845) BI IGF-1 Solid tumors BAY2287411 Bayer Mesothelin Cancer Elgemtumab (LJM716) Novartis HER3 Cancer MOR107 (LP2-3)* - AT2-R Not disclosed NOV–7 (CLG561) Novartis - Eye diseases NOV–8 Novartis - Inflammation NOV-9 (LKA651) Novartis - Diabetic eye diseases NOV-10 (PCA062) Novartis - Cancer NOV-11 Novartis - Blood disorders NOV-13 (HKT288) Novartis - Cancer NOV-14 Novartis - Asthma PRV-300 (CNTO3157) ProventionBio TLR-3 Inflammation Vantictumab (OMP-18R5) OncoMed Fzd 7 Solid tumors 2 12 14 Partnered Discovery Programs Proprietary Development Programs Out-licensed Proprietary Development Programs Most advanced development stage Copyright © 2019 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Proprietary Development Programs © MorphoSys AG, February 2019 Copyright © 2019 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document * For Development in China, Hong Kong, Macao, Taiwan and (MOR210 only) South Korea ** A phase 1 study in healthy volunteers was completed; currently in preclinical investigation © MorphoSys AG, February 2019 Portfolio of Proprietary Development Segment Program Partner Target Disease area Preclinical Phase 1 Phase 2 Phase 3 MOR208 - CD19 DLBCL (B-MIND) DLBCL (L-MIND) CLL (COSMOS) MOR202 I-Mab Biopharma* CD38 Multiple myeloma MOR106 Novartis/ Galapagos IL-17C Atopic dermatitis (iv) Atopic dermatitis (sc) MOR103/ GSK3196165 GSK GM-CSF Inflammation MOR107** - AT2-R Oncology under investigation MOR210 I-Mab Biopharma* C5aR Oncology 6 proprietary or co-developed programs in discovery Proprietary